205 related articles for article (PubMed ID: 16224056)
1. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis.
Koyama H; Shoji T; Yokoyama H; Motoyama K; Mori K; Fukumoto S; Emoto M; Shoji T; Tamei H; Matsuki H; Sakurai S; Yamamoto Y; Yonekura H; Watanabe T; Yamamoto H; Nishizawa Y
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2587-93. PubMed ID: 16224056
[TBL] [Abstract][Full Text] [Related]
2. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes.
Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Umayahara Y; Kosugi K; Yamasaki Y
Atherosclerosis; 2009 May; 204(1):288-92. PubMed ID: 18926539
[TBL] [Abstract][Full Text] [Related]
3. Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE.
Moriya S; Yamazaki M; Murakami H; Maruyama K; Uchiyama S
J Stroke Cerebrovasc Dis; 2014; 23(10):2540-2546. PubMed ID: 25282185
[TBL] [Abstract][Full Text] [Related]
4. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications.
Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Nakatani Y; Ohtoshi K; Hayaishi-Okano R; Kosugi K; Hori M; Yamasaki Y
Diabetes Care; 2005 Nov; 28(11):2716-21. PubMed ID: 16249545
[TBL] [Abstract][Full Text] [Related]
5. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function.
Gohda T; Tanimoto M; Moon JY; Gotoh H; Aoki T; Matsumoto M; Shibata T; Ohsawa I; Funabiki K; Tomino Y
Diabetes Res Clin Pract; 2008 Aug; 81(2):196-201. PubMed ID: 18550199
[TBL] [Abstract][Full Text] [Related]
6. Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease.
Nishizawa Y; Koyama H
J Ren Nutr; 2008 Jan; 18(1):76-82. PubMed ID: 18089449
[TBL] [Abstract][Full Text] [Related]
7. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients.
Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Yamasaki Y
Diab Vasc Dis Res; 2008 Sep; 5(3):190-7. PubMed ID: 18777492
[TBL] [Abstract][Full Text] [Related]
8. Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness.
Choi KM; Yoo HJ; Kim HY; Lee KW; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH
Int J Cardiol; 2009 Feb; 132(1):96-101. PubMed ID: 18190981
[TBL] [Abstract][Full Text] [Related]
9. Association between sRAGE, esRAGE levels and vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography.
Yang SJ; Kim S; Hwang SY; Kim TN; Choi HY; Yoo HJ; Seo JA; Kim SG; Kim NH; Baik SH; Choi DS; Choi KM
Atherosclerosis; 2012 Feb; 220(2):402-6. PubMed ID: 22137663
[TBL] [Abstract][Full Text] [Related]
10. Low plasma levels of the soluble receptor for advanced glycation end products in HIV-infected patients with subclinical carotid atherosclerosis receiving combined antiretroviral therapy.
Jeong SJ; Kim CO; Song YG; Baek JH; Kim SB; Jin SJ; Ku NS; Han SH; Choi JY; Lee HC; Kim JM
Atherosclerosis; 2011 Dec; 219(2):778-83. PubMed ID: 21872861
[TBL] [Abstract][Full Text] [Related]
11. Low Endogenous Secretory Receptor for Advanced Glycation End-Products Levels Are Associated With Inflammation and Carotid Atherosclerosis in Prediabetes.
Di Pino A; Urbano F; Zagami RM; Filippello A; Di Mauro S; Piro S; Purrello F; Rabuazzo AM
J Clin Endocrinol Metab; 2016 Apr; 101(4):1701-9. PubMed ID: 26885882
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis.
Kim JK; Park S; Lee MJ; Song YR; Han SH; Kim SG; Kang SW; Choi KH; Kim HJ; Yoo TH
Atherosclerosis; 2012 Jan; 220(1):208-14. PubMed ID: 21906738
[TBL] [Abstract][Full Text] [Related]
13. Total soluble and endogenous secretory receptor for advanced glycation endproducts (RAGE) in IBD.
Meijer B; Hoskin T; Ashcroft A; Burgess L; Keenan JI; Falvey J; Gearry RB; Day AS
J Crohns Colitis; 2014 Jun; 8(6):513-20. PubMed ID: 24291021
[TBL] [Abstract][Full Text] [Related]
14. Relationship between serum levels of endogenous secretory RAGE and blood pressure in male nondiabetic patients with obstructive sleep apnea.
Cai W; Sun JF; Liu Y; Xu JX; Xiao JR; Duan XM; Liu JY; Zhang W
J Hum Hypertens; 2015 Dec; 29(12):713-8. PubMed ID: 25994997
[TBL] [Abstract][Full Text] [Related]
15. Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease.
Koyama H; Shoji T; Fukumoto S; Shinohara K; Shoji T; Emoto M; Mori K; Tahara H; Ishimura E; Kakiya R; Tabata T; Yamamoto H; Nishizawa Y
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):147-53. PubMed ID: 17082489
[TBL] [Abstract][Full Text] [Related]
16. Association between endogenous secretory receptor for advanced glycation-end products (esRAGE) and carotid intima-media thickness in type 2 diabetes.
Lin X; Chen X; Ye J; Li Q; Zhou J; Wu X; Huang Y; Li X; Shi Y; Li S; Li L; Cai H
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):277-80. PubMed ID: 24839222
[TBL] [Abstract][Full Text] [Related]
17. Increased serum myeloid-related protein 8/14 level is associated with atherosclerosis in type 2 diabetic patients.
Peng WH; Jian WX; Li HL; Hou L; Wei YD; Li WM; Xu YW
Cardiovasc Diabetol; 2011 May; 10():41. PubMed ID: 21592353
[TBL] [Abstract][Full Text] [Related]
18. Endogenous Secretory RAGE as a Novel Biomarker for Metabolic Syndrome and Cardiovascular Diseases.
Koyama H; Yamamoto H; Nishizawa Y
Biomark Insights; 2007 Sep; 2():331-9. PubMed ID: 19662215
[TBL] [Abstract][Full Text] [Related]
19. Metabolic dysfunction in Emirati subjects in Abu Dhabi: Relationship to levels of soluble RAGEs.
Abdulle A; Inman CK; Saleh A; Noshi M; Galani D; Abdelwareth L; Alsafar H; Elfatih A; Al Shamsi H; Ali R; Li H; Ramasamy R; Schmidt AM; Benbarka MM; Hassan MH
J Clin Transl Endocrinol; 2019 Jun; 16():100192. PubMed ID: 31080742
[TBL] [Abstract][Full Text] [Related]
20. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes.
Tan KCB; Chow WS; Tso AWK; Xu A; Tse HF; Hoo RLC; Betteridge DJ; Lam KSL
Diabetologia; 2007 Sep; 50(9):1819-1825. PubMed ID: 17639302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
